Browse
Submit Data
Databases
API
Help

Metabolomics,Unknown,Transcriptomics,Genomics,Proteomics

Dataset Information

8 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Expression data from melanoma cell lines

ABSTRACT: Differential gene expression analysis of parental and resistant sub-lines of melanoma cell lines treated or untreated with PLX4032 Using microarray we sought to obtain a genome-wide profile of differentially expressed genes in parental melanoma cell lines and resistant sub-lines in response to PLX4032 vs DMSO control treatment. Representative parental melanoma cell lines and resistant sub-lines were treated with PLX4032 at 1 uM or DMSO control for 6h. Total RNA was extracted and cDNAs were generated and hybridized onto GeneChip Human Gene 1.0 ST Arrays (Affymetrix).

ORGANISM(S): Homo sapiens

SUBMITTER: Mikyung Lee

PROVIDER: E-GEOD-24862 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress

ACCESS DATA

Json Xml

Publications

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation.

Nazarian Ramin R Shi Hubing H Wang Qi Q Kong Xiangju X Koya Richard C RC Lee Hane H Chen Zugen Z Lee Mi-Kyung MK Attar Narsis N Sazegar Hooman H Chodon Thinle T Nelson Stanley F SF McArthur Grant G Sosman Jeffrey A JA Ribas Antoni A Lo Roger S RS

Nature 20101124 7326

Activating B-RAF(V600E) (also known as BRAF) kinase mutations occur in ∼7% of human malignancies and ∼60% of melanomas. Early clinical experience with a novel class I RAF-selective inhibitor, PLX4032, demonstrated an unprecedented 80% anti-tumour response rate among patients with B-RAF(V600E)-positive melanomas, but acquired drug resistance frequently develops after initial responses. Hypotheses for mechanisms of acquired resistance to B-RAF inhibition include secondary mutations in B-RAF(V600E) ...[more]

PMID: 21107323

Similar Datasets

Expression data from melanoma cell lines

Project description:Differential gene expression analysis of parental and resistant sub-lines of melanoma cell lines treated or untreated with PLX4032 Using microarray we sought to obtain a genome-wide profile of differentially expressed genes in parental melanoma cell lines and resistant sub-lines in response to PLX4032 vs DMSO control treatment.

2010-11-26 | GSE24862 | GEO

Expression data from melanoma cell lines

Project description:Differential gene expression analysis of parental and sub-lines of melanoma cell line resistant to F5 CTL lymphocyte parental melanoma cell line and CTL resistant sub-line

2010-12-01 | E-GEOD-25436 | biostudies-arrayexpress

Wnt5A Enhances Resistance of Melanoma Cells to Targeted BRAF Inhibitors

Project description:About half of all melanomas harbor a constitutively active mutant BRAFV600E/K kinase that can be selectively inhibited by targeted BRAF inhibitors (BRAFi). While patients treated with BRAFi initially exhibit measurable clinical improvement, the majority of patients eventually develop drug resistance and relapse. We observe significant elevation of WNT5A in a subset of tumors from patients exhibiting disease progression on BRAFi therapy. WNT5A transcript and protein are also elevated in BRAFi-resistant melanoma cell lines generated by long-term in vitro treatment with BRAFi. RNAi-mediated reduction in levels of endogenous WNT5A in melanoma decreases cell growth, increases apoptosis in response to BRAFi challenge, and decreases the activity of pro-survival AKT signaling. Overexpression of WNT5A conversely promotes melanoma growth and tumorigenesis and activates AKT signaling. Similar to WNT5A knockdown, knockdown of the WNT receptors FZD7 and RYK inhibits growth, sensitizes melanoma cells to BRAFi, and reduces AKT activation. Together, these findings suggest that chronic BRAF inhibition elevates WNT5A expression, which then acts through FZD7 and RYK to promote AKT signaling, leading to increased growth and therapeutic resistance. Increased WNT5A expression in BRAFi-resistant melanomas also correlates with an associated transcriptional signature, which identifies potential therapeutic targets to reduce clinical resistance to BRAFi. Expression of WNT5A-correlated genes was compared in melanoma cell lines generated to be resistant to PLX4032 and the their associated naïve parental line Basal expression of the WNT5A-correlated genes was also measured in experiments comparing each naïve line to a mixed reference pool containing equal amounts of 47 melanoma cell lines.

2014-03-06 | E-GEOD-55583 | biostudies-arrayexpress

Parent vs. Induced drug tolerant cells Microarray Analysis

Project description:WM164 BRAF mutant Melanoma cells were treated with 500nM PLX4032 for 16 days and their gene expression was compared to parent cells kept in DMSO. WM164 treated and untreated cells were kept in triplicate and the mRNA from individual samples were isolated independently for analysis.

2014-02-06 | E-GEOD-54711 | biostudies-arrayexpress

Expression profiling of BRAFV600E melanoma cell lines upon RAF inhibition

Project description:Microarray expression analysis to identify global changes in transcription in response to RAF inhibition. Genes under RAF control were identified in a panel of BRAFV600E tumor cells, following the short-term inhibition of RAF using a pan-RAF kinase inhibitor, PLX4032 (Plexxikon). For comparison with changes in gene expression in response to MEK inhibition using PD0325901 (Pfizer), the following array data was referenced: (http://www.ncbi.nlm.nih.gov/geo/ (accession no. GSE10086)). Cell lines growing in culture (n=5) were treated with the RAF inhibitor PLX4032 (250nM or 1000nM) or vehicle alone (0.1% DMSO) as control, for eight hours.

2010-07-18 | E-GEOD-20051 | biostudies-arrayexpress

Expression data from melanoma cell lines

Project description:Differential gene expression analysis of parental and sub-lines of melanoma cell line resistant to F5 CTL lymphocyte

2010-12-01 | GSE25436 | GEO

MITF ChIP-seq in primary melanocyte and melanoma as a function of oncogenic BRAF

Project description:Thousands of enhancers are characterized in the human genome, yet few have been shown important in cancer. Inhibiting oncokinases, such as EGFR, ALK, HER2, and BRAF, is a mainstay of current cancer therapy but is hindered by innate drug resistance mediated by upregulation of the HGF receptor, MET. The mechanisms mediating such genomic responses to targeted therapy are unknown. Here, we identify lineage-specific MET enhancers for multiple common tumor types, including a melanoma lineage-specific MET enhancer that displays inducible chromatin looping and MET gene induction upon BRAF inhibition. Epigenomic analysis demonstrated that the melanocyte-specific transcription factor, MITF, mediates this enhancer function. Targeted genomic deletion (<7bp) of the MITF motif within the MET enhancer suppressed inducible chromatin looping and innate drug resistance, while maintaining MITF-dependent, inhibitor-induced melanoma cell differentiation. Epigenomic analysis can thus guide functional disruption of regulatory DNA to decouple pro- and anti-oncogenic functions of tumor lineage-enriched transcription factors mediating innate resistance to oncokinase therapy. MITF ChIP-seq was performed in primary human melanocytes with overexpression of BRAFV600E or a lentiviral control (RFP), and in COLO829 melanoma cells treated with DMSO, or PLX4032

2014-01-14 | E-GEOD-50681 | biostudies-arrayexpress

Genome-wide copy number variation in human metastatic melanoma cell lines

Project description:Illumina HumanExon510S-DUO bead arrays (Illumina Inc) were performed according to the manufacturer's protocol. Genome-wide copy number variation analysis was performed on the genomic DNA of two pairs of cell lines comprising of parental melanoma cell lines and corresponding resistant sub-lines.

2010-11-26 | E-GEOD-24890 | biostudies-arrayexpress

Parent vs. Induced drug tolerant cells Microarray Analysis

Project description:WM164 BRAF mutant Melanoma cells were treated with 500nM PLX4032 for 16 days and their gene expression was compared to parent cells kept in DMSO.

2014-02-06 | GSE54711 | GEO

Epigenome analysis of Control and PLX4032 Resistant Clones with EPIC array.

Project description:Genome wide DNA methylation profiling of control and PLX4032 resistant clones to identify resistance-associated methylome alternations, and to integrate with transcriptome analysis. Results provide insight into clonal epigentic adaption of PLX4032 resistance in BRAF V600E melanoma.

2020-09-20 | GSE137452 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data